LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE...
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12...
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of...
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW...
LPAD may provide alternative pathways for streamlined product approvalLOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023SAN DIEGO, June 20, 2023...
PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height...
Parties consider collaborative agreement for the collection and conversion of anesthetic gasesTORONTO, June 19, 2023 (GLOBE NEWSWIRE) -- Blue-Zone Technologies...
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean...
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses...
Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of...
YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear,...
Per Protocol Participants saw an 85% Reduction in the Loss of Vertebral Bone Density in One YearCHICAGO, June 16, 2023...
PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento...
MINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., June...
SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its...
SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on...